FDA approves Aurobindo’s Renvela generic

EAST WINDSOR, N.J. — Aurobindo Pharma USA on Monday announced that its had received Food and Drug Administration approval for its generic of Genzyme’s Renvela (sevelamer carbonate for oral suspension).

The drug is indicated for the control of serum phosphorus in patients with chronic kidney disease.

Aurobindo’s generic will be available in 08.- and 2.4-g pouches. The drug had a market size of $139.9 million for the 12 months ended April 2017, according to QuintilesIMS data.